Chemed Corp: Form 10-Q for the period ended Mar 31, 2020
Filed with the SEC on May 1, 2020 and accepted by EDGAR at May 1, 2020, 08:01 ET.
Management's discussion and analysis
As filed, 44,612 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Executive Summary
We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.
The following is a summary of the key operating results (in thousands except per share amounts):
| Three months ended March 31, 2020 | 2019 | |
|---|---|---|
| Service revenues and sales | $515,798 | $462,034 |
| Net income | $55,891 | $44,667 |
| Diluted EPS | $3.38 | $2.70 |
| Adjusted net income | $60,715 | $48,175 |
| Adjusted diluted EPS | $3.68 | $2.92 |
| Adjusted EBITDA | $93,029 | $74,798 |
| Adjusted EBITDA as a % of revenue | 18.0% | 16.2% |
Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 32-33.
For the three months ended March 31, 2020, the increase in consolidated service revenues and sales was driven by a 14.6% increase at Roto-Rooter and a 10.1% increase at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in all major service lines as well as a result of acquisitions completed in 2019. The increase in service revenues at VITAS is comprised primarily of a 5.9% increase in days-of-care, a geographically weighted average Medicare reimbursement rate increase of approximately 5.0%, and acuity mix shift which then reduced the Medicare rate increase approximately 0.9%. See page 34 for additional VITAS operating metrics.
The recent COVID-19 pandemic could have a material adverse effect on our business operations, results of operations, cash flow and financial position. We are closely monitoring the impact of the pandemic on all aspects of our business including impacts to employees, customers, patients, suppliers and vendors. The Company’s two operating subsidiaries have been categorized as critical infrastructure businesses and are not currently materially limited by federal, state or local regulations that restrict movement or operating ability.
The continued health of our workforce cannot be predicted during the pandemic. Significant shortages of labor could inhibit the ability of both VITAS and Roto-Rooter to perform services. The inability to procure personal-protective equipment, and to protect worker health and customer safety, could negatively impact the health of our workforce. A portion of our workforce is currently working from remote locations on a regular basis which increases both operational and cybersecurity risks.
VITAS is working closely with hospitals, doctors and other healthcare providers. The response of these healthcare providers to the pandemic may limit VITAS’ ability to provide care and may result in fewer referrals. A prolonged or severe economic downturn may significantly impact Roto-Rooter’s service revenue. A significant disruption in the supply chain for critical items needed by either VITAS or Roto-Rooter could inhibit our ability to provide services or significantly increase the cost of providing those services.
The length and severity of the pandemic, coupled with related governmental actions including relief acts and actions relating to our workforce at federal, state and local levels, and underlying economic disruption will determine the ultimate short-term and long-term impact to our business operations and financial results. We are unable to predict the myriad of possible issues that could arise or the ultimate effect to our businesses as a result of the unknown short, medium and long-term impacts that the pandemic will have on the United States economy and society as a whole.
Identified direct costs incurred for the three-months ended March 31, 2020 related to COVID-19 are $1.8 million. These costs are comprised primarily of additional expected credit losses at Roto-Rooter, additional personal protective equipment and sanitizing supplies at both VITAS and Roto-Rooter and paid time-off for employees potentially directly affected by COVID-19. These costs do not include estimates for lost revenue, operational inefficiencies related to excess utilization of supplies, equipment and field staffing, diversion of existing infrastructure resources to allow for operating during a pandemic, or diversion of management and administrative time to address COVID-19 issues, while continuing to operate both business segments. We anticipate costs during the second quarter of 2020 and the remainder of calendar 2020 to be significantly higher than what were incurred during the first quarter of 2020, given the timing of the onset and spread of the pandemic. Additionally, VITAS implemented a program that awards more than 10,000 frontline employees an additional two weeks of paid time off (“PTO”) in 2020. VITAS estimates the additional PTO to cost approximately $23.2 million, prior to employee benefit and payroll tax costs.
On March 27, 2020, the CARES Act was passed. It is intended to provide economic relief to individuals and businesses affected by the coronavirus pandemic. It also contains provisions related to healthcare providers’ operations and the issues caused by the coronavirus pandemic. The following significant economic impacts for Chemed and its subsidiaries as a result of specific provisions of the CARES Act:
Chemed deferred its first quarter 2020 income tax payment of $8.8 million to the Federal government until July 15, 2020, as permitted by the CARES Act. In addition, Chemed and its subsidiaries deferred payment of certain employer payroll taxes and certain state tax payments, as permitted by the CARES Act.
A portion of the CARES Act provides $100 billion from the Public Health and Social Services Emergency Fund (“Relief Fund”) to hospitals and other healthcare providers on the front lines of the coronavirus response. Of this $100 billion distribution from the Relief Fund, $30 billion was designated to be automatically distributed to facilities and healthcare providers based upon their 2019 Medicare fee-for-service revenue. On April 10, 2020 VITAS automatically received $80.2 million from the Relief Fund based upon VITAS’s 2019 Medicare fee-for-service Medicare revenue. While specific details of the program have not been announced, recipients of this $30 billion in CARES Act relief are specified to use these funds to prevent, prepare for, and respond to coronavirus, and shall reimburse the recipient only for health care related expenses or lost revenues that are attributable to coronavirus. The ability of VITAS to retain and utilize the full $80.2 million from the Relief Fund will depend on the magnitude, timing and nature of the economic impact of COVID-19 within VITAS, as well as the guidelines and rules of the Relief Fund program.
During the period from May 1, 2020 through December 31, 2020, the 2% sequestration reimbursement cut is suspended. VITAS anticipates this will increase revenue approximately $15 million to $20 million, excluding the impact of the Medicare Cap.
In addition to the economic impacts, the CARES Act coupled with a series of waivers and guidance issued by the Centers for Medical and Medicaid Services (“CMS”) suspended various Medicare patient coverage criteria and documentation, as well as care requirements. For VITAS, the relief includes the temporary waiver of the requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides. Additionally, CMS permitted expanded use of telehealth in providing hospice care to patients.
The situation surrounding COVID-19 remains fluid. We evaluate our cash flow, liquidity and capital resources on a daily basis. VITAS and Roto-Rooter continue to operate and have positive net income and operating cash flow. We have $252.1 million available for borrowing under our $450 million revolving line-of-credit.
On August 6, 2019, the Centers for Medicare and Medicaid Services released the fiscal year 2020 hospice wage index and payment rate update (FY 2020 update). The FY 2020 update includes the normal yearly inflationary increase by level of care plus a rebasing of the continuous care, inpatient care and respite care rates. The rebasing of these levels of care was to reflect non-inflationary changes in providers’ costs over time. The rebasing increased the national average reimbursement rate for continuous care by 39.9% and inpatient care by 34.7%. Respite care is not material to our operations. The rebasing of these levels of care was effective on October 1, 2019.
On August 2, 2019, we entered into an Asset Purchase Agreement (the “Agreement”) to purchase substantially all of the assets of HSW RR, Inc., a Delaware corporation (“HSW”) and certain related assets of its affiliates, for $120 million, subject to a working capital adjustment. HSW owned and operated fourteen Roto-Rooter franchises mainly in the southwestern section of the United States, including Los Angeles, Dallas and Phoenix. Included in the assets purchased were the assets of Western Drain Supply, Inc., a plumbing supply company. The purchase was made using a combination of cash on-hand and borrowings under Chemed’s existing $450 million revolving credit facility. On September 16, 2019, we completed the acquisition.
On July 1, 2019, we completed the acquisition of a Roto-Rooter franchise and the related assets in Oakland, CA for $18.0 million in cash.
Reacquired franchise rights, included in identifiable intangibles on the Consolidated Balance Sheets, are amortized over the period remaining in each individual franchise agreement. The average amortization period for reacquired franchise rights for the acquisitions made in the third quarter of 2019 is 7.4 years.
The franchise fee revenue, the valuation of reacquired franchise rights and amortization for the acquired franchises are as follows:
- 23-
| 2018 Franchise Revenue | Valuation of Reacquired Franchise Rights | Multiple of Annual Franchise Fees to Reacquired Franchise Rights | Annualized Amortization of Reacquired Franchise Rights | ||
|---|---|---|---|---|---|
| HSW | $1,782 | $52,980 | 29.7 | yrs | $7,258 |
| Oakland | 95 | 6,190 | 65.2 | 825 | |
| Subtotal | 1,877 | $59,170 | 31.5 | yrs | $8,083 |
| All other franchise territories | 4,505 | ||||
| $6,382 |
Amortization of reacquired franchise agreements comprises the following (in thousands):
| Three months ended March 31, 2020 | 2019 |
|---|---|
| $2,352 | $441 |
Regarding our outlook for 2020, operating during the pandemic has the potential to materially impact the operational metrics and overall operating results of the Company. However, it is expected that the CARES Act funds received by Vitas will be sufficient to substantially offset anticipated costs and lost revenue related to the COVID-19 pandemic. Roto-Rooter is anticipated to receive minimal financial support from the CARES Act. However, it is important to consider Roto-Rooter’s main service is to stop water and raw sewage from flowing and causing destruction to residential and commercial structures. It is primarily a necessity and grudge service that has historically been resistant to even the deepest of recessions. We are early into the disruption caused by the COVID-19 pandemic and related shutdown of significant portions of our economy. It is premature, and in fact impossible, to reasonably measure or predict the impact COVID-19 will have on Roto-Rooter’s full year 2020 operating results. Recognizing these issues, we anticipate providing updated 2020 earnings guidance when we issue our second quarter 2020 operating results.
Financial Condition
Liquidity and Capital Resources
Material changes in the balance sheet accounts from December 31, 2019 to March 31, 2020 include the following:
A $22.8 million increase in cash and cash equivalents due to timing of payments from the Federal government.
A $9.1 million decrease in accounts receivable due to timing of receipts.
A $5.2 million decrease in investments of deferred compensation plans and a $6.1 million decrease in deferred compensation liabilities due to stock market losses and retirement payments made from the plan.
A $13.3 million decrease in accounts payable due to timing of payments.
A $6.2 million increase in accrued insurance related to the timing of policy years.
A $7.2 million decrease in accrued compensation due to the payments of cash bonuses in the first quarter of 2020.
A $70.0 million increase in long-term debt due mainly due to borrowings related to stock repurchases.
A $111.5 million increase in treasury stock due mainly to stock repurchases.
Net cash provided by operating activities increased $15.7 million from March 31, 2019 to March 31, 2020. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $40.0 million from the Federal government from hospice services every other Friday. The timing of period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two year period, as cash flow variations in one year are offset in the following year.
Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.
On June 20, 2018, we replaced our existing credit agreement with the Fourth Amended and Restated Credit Agreement (“2018 Credit Agreement”). Terms of the 2018 Credit Agreement consist of a five year, $450 million revolving credit facility and a $150 million expansion feature, which may consist of term loans or additional revolving commitments. The revolving credit facility has a five year maturity with principal payments due at maturity. The interest rate at the inception of the agreement was LIBOR plus 100 basis points.
The 2018 Credit Agreement has a floating interest rate that is generally LIBOR plus a tiered additional rate which varies based on our current leverage ratio.
We have issued $37.9 million in standby letters of credit as of March 31, 2020, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of March 31, 2020, we have approximately $252.1 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.
Commitments and Contingencies
Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2020 and anticipate remaining in compliance throughout the foreseeable future.
The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, which can result in penalties including repayment obligations, funding withholding, or debarment, as well as to lawsuits, including qui tam actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. Other than as described below, it is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or reasonably estimable.
On October 30, 2017, the Company entered into a settlement agreement (the “Settlement Agreement”) to resolve civil litigation under the False Claims Act brought by the United States Department of Justice (“DOJ”) on behalf of the OIG and various relators concerning VITAS, filed in the U.S. District Court of the Western District of Missouri. The Company denied any violation of law and agreed to settlement without admission of wrongdoing.
In connection with the settlement VITAS and certain of its subsidiaries entered into a corporate integrity agreement (“CIA”) on October 30, 2017. The CIA formalizes various aspects of VITAS’ already existing Compliance Program and contains requirements designed to document compliance with federal healthcare program requirements. It has a term of five years during which it imposes monitoring, reporting, certification, oversight, screening and training obligations, certain of which had previously been implemented by VITAS. It also requires VITAS to engage an Independent Review Organization to perform audit and review functions and to prepare reports regarding compliance with federal healthcare programs. In the event of breach of the CIA, VITAS could become liable for payment of stipulated penalties or could be excluded from participation in federal healthcare programs.
The Company entered into a settlement agreement in March 2019 that will resolve state-wide wage and hour class action claims raised in four separate cases: (1) Jordan A. Seper on behalf of herself and others similarly situated v. VITAS Healthcare Corporation of California, a Delaware corporation; VITAS Healthcare Corp of CA, a business entity unknown; and DOES 1 to 100, inclusive; Los Angeles Superior Court Case Number BC 642857 (“Seper”); (2) Jiwan Chhina v. VITAS Health Services of California, Inc., a California corporation; VITAS Healthcare Corporation of California, a Delaware corporation; VITAS Healthcare Corporation of California, a Delaware corporation dba VITAS Healthcare Inc.; and DOES 1 to 100, inclusive; San Diego Superior Court Case Number 37-2015-00033978-CU-OE-CTL (“Chhina”) (which was subsequently merged with Seper); (3) Chere Phillips and Lady Moore v. VITAS Healthcare Corporation of California, Sacramento County Superior Court, Case No. 34-2017-0021-2755 (“Phillips and Moore”); and (4) Williams v. VITAS Healthcare Corporation of California, Alameda County Superior Court Case No. RG 17853886 (“Williams’). These actions were brought by both current and former employees including a registered nurse, a licensed vocational nurse (LVN), home health aides and a social worker. Each action stated multiple claims generally including (1) failure to pay minimum wage for all hours worked; (2) failure to provide overtime for all hours worked; (3) failure to pay wages for all hours at the regular rate; (4) failure to provide meal periods; (5) failure to provide rest breaks; (6) failure to provide complete and accurate wage statements; (7) failure to pay for all reimbursement expenses; (8) unfair business practices; and (9) violation of the California Private Attorneys General Act. The cases generally asserted claims on behalf of classes defined to include all current and former non-exempt employees employed with VITAS in California within the four years preceding the filing of each lawsuit. For additional procedural history of these cases, please refer to our prior quarterly and annual filings.
The Seper and Chhina cases were consolidated in Los Angeles County Superior Court; Chhina was dismissed as a separate action and joined with Seper in the filing of amended complaint on August 28, 2018, in which both Chhina and Seper were identified as named plaintiffs. Discovery in the remaining cases was stayed as to class claims and each court was advised of the pendency of the consolidated Seper/Chhina action. The parties engaged in a mediation process beginning in October 2018 and concluded with an agreement in March 2019. The settlement amount of $5.75 million plus employment taxes. was recorded in the first quarter of 2019. As of December 31, 2019, $6.0 million was accrued in the accompanying Consolidated Balance Sheet. The definition of the class to participate in the settlement is intended to cover claims raised in the consolidated Seper/Chhina matter, claims raised in Phillips and Moore, as well as any class claims in Williams. On January 28, 2020, the court granted preliminary approval of the settlement. A notice of the proposed settlement has been sent to the members of the class by the class claims administrator. The court has set the date for the final approval of the settlement hearing for May 21, 2020.
Alfred Lax (“Lax”), a current employee of Roto-Rooter Services Company (“RRSC”), was hired in RRSC’s Menlo Park branch in 2007. On November 30, 2018, Lax filed a class action lawsuit in Santa Clara County Superior Court alleging (1) failure to provide or compensate for required rest breaks; (2) failure to properly pay for all hours worked; (3) failure to provide accurate wage statements; (4) failure to reimburse for work-related expenses; and (5) unfair business practices. Lax stated these claims as a representative of a class defined as all service technicians employed by RRSC in California during the four years preceding the filing of the complaint. He seeks a determination that the action may proceed and be maintained as a class action and for compensatory and statutory damages (premium payments for missed rest periods, uncompensated rest periods, wages for time allegedly not paid such as travel time, repair time, and vehicle maintenance time, and unreimbursed expenses), penalties and restitutions, pre- and post-judgement interest and attorneys’ fees and costs. The lawsuit is, Alfred Lax on behalf of himself and all others similarly situated v. Roto-Rooter Services Company, and Does 1 through 50 inclusive; Santa Clara County Superior Court Case Number 18CV338652.
The Company is not able to reasonably estimate the probability of loss or range of loss for any of these lawsuits at this time, with the exception of Seper/Chhina, Phillips and Moore and the class claims in Williams.
The Company intends to defend vigorously against the allegations in the Lax lawsuit. Regardless of the outcome of any of the preceding matters, dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, withholding of governmental funding, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.
Results of Operations
Three months ended March 31, 2020 versus 2019 - Consolidated Results
Our service revenues and sales for the first quarter of 2020 increased 11.6% versus services and sales revenues for the first quarter of 2019. Of this increase, a $31.1 million increase was attributable to VITAS and $22.6 million increase was attributable to Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):
| VITAS | Three months ended March 31, 2020 | 2019 |
|---|---|---|
| Routine homecare | $271,762 | $258,847 |
| Continuous care | 40,555 | 32,244 |
| General inpatient | 32,482 | 22,570 |
| Other | 3,147 | 2,010 |
| Medicare cap adjustment | (2,500) | (3,400) |
| Room and board - net | (3,381) | (2,542) |
| Implicit price concessions | (4,149) | (2,948) |
| Roto-Rooter | ||
| Drain cleaning - short term core | 54,020 | 44,653 |
| Plumbing - short term core | 36,794 | 32,418 |
| Subtotal | 90,814 | 77,071 |
| Excavation - short term core | 43,060 | 34,538 |
| Water restoration | 29,246 | 29,208 |
| Contractor operations | 16,228 | 14,032 |
| Outside franchisee fees | 1,190 | 1,621 |
| Other - short term core | 550 | 576 |
| Other | 3,534 | 3,008 |
| Implicit price concessions | (6,740) | (4,801) |
| Total | $515,798 | $462,034 |
- 26-
Days of care at VITAS during the quarter ended March 31 were as follows:
| Days of Care 2020 | 2019 | Increase/(Decrease) Percent | |
|---|---|---|---|
| Routine homecare | 1,364,746 | 1,281,899 | 6.5 |
| Nursing home | 303,374 | 289,769 | 4.7 |
| Respite | 6,692 | 6,301 | 6.2 |
| Subtotal routine homecare and respite | 1,674,812 | 1,577,969 | 6.1 |
| Continuous care | 32,348 | 29,150 | 11.0 |
| General inpatient | 41,373 | 43,923 | (5.8) |
| Total days of care | 1,748,533 | 1,651,042 | 5.9 |
The revenue increase at VITAS is comprised primarily of the 5.9% increase in days-of-care, a geographically weighted average Medicare reimbursement rate increase of approximately 5.0%, and acuity mix shift which then reduced the Medicare rate increase approximately 0.9%.
The increase in plumbing revenues for the first quarter of 2020 versus 2019 is attributable to a 13.1% increase in price and service mix shift and an 0.4% increase in job count. The increase in excavation revenues for the first quarter of 2020 versus 2019 is attributable to a 5.7% increase in price and service mix shift and a 19.0% increase in job count. Drain cleaning revenues for the first quarter of 2020 versus 2019 reflect a 8.5% increase in price and service mix shift and a 12.5% increase in job count. Water restoration revenue for the first quarter of 2020 versus 2019 is attributable to a 4.2% increase in job count offset by a 4.1% decrease in price. Contractor operations increased 15.6% mainly due to their continued expansion into water restoration.
The consolidated gross margin was 31.8% in the first quarter of 2020 as compared with 30.3% in the first quarter of 2019. On a segment basis, VITAS’ gross margin was 23.2% in the first quarter of 2020 as compared with 21.9%, in the first quarter of 2019 primarily due to increased revenue. The Roto-Rooter segment’s gross margin was 48.1% for the first quarter of 2020 as compared with 47.0% in the first quarter of 2019 primarily due to increased revenue.
Selling, general and administrative expenses (“SG&A”) comprise (in thousands):
| Three months ended March 31, 2020 | 2019 | |
|---|---|---|
| SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts | $78,334 | $70,203 |
| Impact of market value adjustments related to assets held in deferred compensation trusts | (9,572) | 2,338 |
| Long-term incentive compensation | 1,821 | 1,488 |
| Total SG&A expenses | $70,583 | $74,029 |
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first quarter of 2020 were up 11.6% when compared to the first quarter of 2019. This increase was mainly a result of the increase in variable selling and general administrative expenses caused by increased revenue.
Depreciation for the first quarter of 2020, increased 17.3% when compared to the first quarter of 2019, primarily due to new equipment purchased at Roto-Rooter related to the acquisitions completed in the second half of 2019.
Amortization for the first quarter of 2020, increased 377.3% when compared to the first quarter of 2019 due to the amortization of reacquired franchise rights related to acquisitions completed in the second half of 2019.
Other operating expenses decreased $6.1 million from the first quarter of 2019 primarily as a result of a $6.0 million litigation settlement at VITAS recorded in the first quarter of 2019.
Other (expense)/income – net comprise (in thousands):
| Market value adjustment on assets held in | Three months ended March 31, 2020 | 2019 |
|---|---|---|
| deferred compensation trust | $(9,572) | $2,338 |
| Interest income | 106 | 101 |
| Total other (expense)/income - net | $(9,466) | $2,439 |
Our effective tax rate reconciliation is as follows:
| Three months ended March 31, 2020 | 2019 | |
|---|---|---|
| Income tax provision calculated at the statutory federal rate | $14,474 | $10,665 |
| Stock compensation tax benefits | (4,553) | (6,732) |
| State and local income taxes | 2,377 | 1,128 |
| Other--net | 733 | 1,059 |
| Income tax provision | $13,031 | $6,120 |
| Effective tax rate | 18.9% | 12.1% |
Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):
| VITAS | Three months ended March 31, 2020 | 2019 |
|---|---|---|
| Direct costs related to COVID-19 | $(726) | $- |
| Medicare cap sequestration adjustment | (503) | (387) |
| Litigation settlement | - | (4,476) |
| Non cash ASC 842 expenses | - | (489) |
| Roto-Rooter | ||
| Amortization of reacquired franchise agreements | (1,729) | (324) |
| Direct costs related to COVID-19 | (633) | - |
| Non cash ASC 842 expenses | - | (40) |
| Corporate | ||
| Excess tax benefits on stock compensation | 4,553 | 6,732 |
| Stock option expense | (4,190) | (3,327) |
| Long-term incentive compensation | (1,596) | (1,230) |
| Non cash ASC 842 expenses | - | 124 |
| Acquisition expense | - | (91) |
| Total | $(4,824) | $(3,508) |
Three months ended March 31, 2020 versus 2019 - Segment Results
Net income/(loss) for the first quarter of 2020 versus the first quarter of 2019 by segment (in thousands):
| Three months ended March 31, 2020 | 2019 | |
|---|---|---|
| VITAS | $41,279 | $29,288 |
| Roto-Rooter | 24,322 | 22,986 |
| Corporate | (9,710) | (7,607) |
| $55,891 | $44,667 |
VITAS’ after-tax earnings were positively impacted in 2020 compared to 2019 due to higher revenue and improved labor management and ancillary costs. After-tax earnings as a percent of revenue at VITAS in the first quarter of 2020 was 12.2% as compared to 9.5% in the first quarter of 2019.
Roto-Rooter’s net income was impacted in 2020 compared to 2019 primarily by higher revenue offset by increased amortization expense. After-tax earnings as a percent of revenue at Roto-Rooter in the first quarter of 2020 was 13.7% as compared to 14.8% in the first quarter of 2019.
After-tax Corporate expenses for 2020 increased 27.6% when compared to 2019 due mainly to a $2.2 million decrease in the excess tax benefits on stock compensation.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2020
(in thousands)(unaudited)
| 2020 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
|---|---|---|---|---|
| Service revenues and sales | $337,916 | $177,882 | $- | $515,798 |
| Cost of services provided and goods sold | 259,429 | 92,316 | - | 351,745 |
| Selling, general and administrative expenses | 22,269 | 46,282 | 2,032 | 70,583 |
| Depreciation | 5,474 | 5,878 | 36 | 11,388 |
| Amortization | 18 | 2,459 | - | 2,477 |
| Other operating expenses | 114 | 128 | - | 242 |
| Total costs and expenses | 287,304 | 147,063 | 2,068 | 436,435 |
| Income/(loss) from operations | 50,612 | 30,819 | (2,068) | 79,363 |
| Interest expense | (45) | (102) | (828) | (975) |
| Intercompany interest income/(expense) | 4,386 | 1,349 | (5,735) | - |
| Other income—net | 65 | 40 | (9,571) | (9,466) |
| Income/(expense) before income taxes | 55,018 | 32,106 | (18,202) | 68,922 |
| Income taxes | (13,739) | (7,784) | 8,492 | (13,031) |
| Net income/(loss) | $41,279 | $24,322 | $(9,710) | $55,891 |
| (a) The following amounts are included in net income (in thousands): | ||||
| Chemed | ||||
| VITAS | Roto-Rooter | Corporate | Consolidated | |
| Pretax benefit/(cost): | ||||
| Stock option expense | $- | $- | $(5,045) | $(5,045) |
| Amortization of reacquired franchise agreements | - | (2,352) | - | (2,352) |
| Direct costs related to COVID-19 | (973) | (861) | - | (1,834) |
| Long-term incentive compensation | - | - | (1,821) | (1,821) |
| Medicare cap sequestration | (675) | - | - | (675) |
| Total | $(1,648) | $(3,213) | $(6,866) | $(11,727) |
| Chemed | ||||
| VITAS | Roto-Rooter | Corporate | Consolidated | |
| After-tax benefit/(cost): | ||||
| Stock option expense | $- | $- | $(4,190) | $(4,190) |
| Amortization of reacquired franchise agreements | - | (1,729) | - | (1,729) |
| Long-term incentive compensation | - | - | (1,596) | (1,596) |
| Direct costs related to COVID-19 | (726) | (633) | - | (1,359) |
| Medicare cap sequestration | (503) | - | - | (503) |
| Excess tax benefits on stock compensation | - | - | 4,553 | 4,553 |
| Total | $(1,229) | $(2,362) | $(1,233) | $(4,824) |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2019
(in thousands)(unaudited)
| 2019 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
|---|---|---|---|---|
| Service revenues and sales | $306,781 | $155,253 | $- | $462,034 |
| Cost of services provided and goods sold | 239,743 | 82,208 | - | 321,951 |
| Selling, general and administrative expenses | 21,536 | 39,601 | 12,892 | 74,029 |
| Depreciation | 4,708 | 4,963 | 39 | 9,710 |
| Amortization | 18 | 501 | - | 519 |
| Other operating expenses | 6,354 | (1) | - | 6,353 |
| Total costs and expenses | 272,359 | 127,272 | 12,931 | 412,562 |
| Income/(loss) from operations | 34,422 | 27,981 | (12,931) | 49,472 |
| Interest expense | (47) | (95) | (982) | (1,124) |
| Intercompany interest income/(expense) | 4,394 | 2,195 | (6,589) | - |
| Other income—net | 88 | 14 | 2,337 | 2,439 |
| Income/(expense) before income taxes | 38,857 | 30,095 | (18,165) | 50,787 |
| Income taxes | (9,569) | (7,109) | 10,558 | (6,120) |
| Net income/(loss) | $29,288 | $22,986 | $(7,607) | $44,667 |
| (a) The following amounts are included in net income (in thousands): | ||||
| Chemed | ||||
| VITAS | Roto-Rooter | Corporate | Consolidated | |
| Pretax benefit/(cost): | ||||
| Litigation settlement | $(6,000) | $- | $- | $(6,000) |
| Stock option expense | - | - | (4,089) | (4,089) |
| Long-term incentive compensation | - | - | (1,488) | (1,488) |
| Non cash ASC 842 (expenses)/benefit | (656) | (55) | 163 | (548) |
| Medicare cap sequestration adjustment | (515) | - | - | (515) |
| Acquisition expenses | - | (441) | - | (441) |
| Amortization of reacquired franchise agreements | - | - | (120) | (120) |
| Total | $(7,171) | $(496) | $(5,534) | $(13,201) |
| Chemed | ||||
| VITAS | Roto-Rooter | Corporate | Consolidated | |
| After-tax benefit/(cost): | ||||
| Litigation settlement | $(4,476) | $- | $- | $(4,476) |
| Stock option expense | - | - | (3,327) | (3,327) |
| Long-term incentive compensation | - | - | (1,230) | (1,230) |
| Non cash ASC 842 (expenses)/benefit | (489) | (40) | 124 | (405) |
| Medicare cap sequestration adjustment | (387) | - | - | (387) |
| Acquisition expenses | - | (324) | - | (324) |
| Amortization of reacquired franchise agreements | - | - | (91) | (91) |
| Excess tax benefits on stock compensation | - | 6,732 | 6,732 | |
| Total | $(5,352) | $(364) | $2,208 | $(3,508) |
Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA
(in thousands)
| Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2020 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
|---|---|---|---|---|
| Net income/(loss) | $41,279 | $24,322 | $(9,710) | $55,891 |
| Add/(deduct): | ||||
| Interest expense | 45 | 102 | 828 | 975 |
| Income taxes | 13,739 | 7,784 | (8,492) | 13,031 |
| Depreciation | 5,474 | 5,878 | 36 | 11,388 |
| Amortization | 18 | 2,459 | - | 2,477 |
| EBITDA | 60,555 | 40,545 | (17,338) | 83,762 |
| Add/(deduct): | ||||
| Intercompany interest expense/(income) | (4,386) | (1,349) | 5,735 | - |
| Interest income | (68) | (40) | - | (108) |
| Stock option expense | - | - | 5,045 | 5,045 |
| Direct costs related to COVID-19 | 973 | 861 | - | 1,834 |
| Long-term incentive compensation | - | - | 1,821 | 1,821 |
| Medicare cap sequestration adjustment | 675 | - | - | 675 |
| Adjusted EBITDA | $57,749 | $40,017 | $(4,737) | $93,029 |
| Chemed | ||||
| For the three months ended March 31, 2019 | VITAS | Roto-Rooter | Corporate | Consolidated |
| Net income/(loss) | $29,288 | $22,986 | $(7,607) | $44,667 |
| Add/(deduct): | ||||
| Interest expense | 47 | 95 | 982 | 1,124 |
| Income taxes | 9,569 | 7,109 | (10,558) | 6,120 |
| Depreciation | 4,708 | 4,963 | 39 | 9,710 |
| Amortization | 18 | 501 | - | 519 |
| EBITDA | 43,630 | 35,654 | (17,144) | 62,140 |
| Add/(deduct): | ||||
| Intercompany interest expense/(income) | (4,394) | (2,195) | 6,589 | - |
| Interest income | (88) | (14) | - | (102) |
| Litigation settlement | 6,000 | - | - | 6,000 |
| Non cash ASC 842 expenses/(benefit) | 656 | 55 | (163) | 548 |
| Medicare cap sequestration adjustment | 515 | - | - | 515 |
| Acquisition expense | - | - | 120 | 120 |
| Stock option expense | - | - | 4,089 | 4,089 |
| Long-term incentive compensation | - | - | 1,488 | 1,488 |
| Adjusted EBITDA | $46,319 | $33,500 | $(5,021) | $74,798 |
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)
| Three Months Ended March 31, 2020 | 2019 | |
|---|---|---|
| Net income as reported | $55,891 | $44,667 |
| Add/(deduct) pre-tax cost of: | ||
| Stock option expense | 5,045 | 4,089 |
| Amortization of reacquired franchise agreements | 2,352 | 441 |
| Direct costs related to COVID-19 | 1,834 | - |
| Long-term incentive compensation | 1,821 | 1,488 |
| Medicare cap sequestration adjustment | 675 | 515 |
| Litigation settlement | - | 6,000 |
| Acquisition expense | - | 120 |
| Non cash ASC 842 expense | - | 548 |
| Add/(deduct) tax impacts: | ||
| Tax impact of the above pre-tax adjustments (1) | (2,350) | (2,961) |
| Excess tax benefits on stock compensation | (4,553) | (6,732) |
| Adjusted net income | $60,715 | $48,175 |
| Diluted Earnings Per Share As Reported | ||
| Net income | $3.38 | $2.70 |
| Average number of shares outstanding | 16,516 | 16,525 |
| Adjusted Diluted Earnings Per Share | ||
| Adjusted net income | $3.68 | $2.92 |
| Adjusted average number of shares outstanding | 16,516 | 16,525 |
| (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |
- 33-
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
| OPERATING STATISTICS Net revenue ($000) | Three Months Ended March 31, 2020 | 2019 |
|---|---|---|
| Homecare | $271,762 | $258,847 |
| Inpatient | 32,482 | 22,570 |
| Continuous care | 40,555 | 32,244 |
| Other | 3,147 | 2,010 |
| Subtotal | $347,946 | $315,671 |
| Room and board, net | (3,381) | (2,542) |
| Contractual allowances | (4,149) | (2,948) |
| Medicare cap allowance | (2,500) | (3,400) |
| Total | $337,916 | $306,781 |
| Net revenue as a percent of total before Medicare cap allowances | ||
| Homecare | 78.1% | 82.0% |
| Inpatient | 9.3 | 7.1 |
| Continuous care | 11.7 | 10.2 |
| Other | 0.9 | 0.7 |
| Subtotal | 100.0 | 100.0 |
| Room and board, net | (1.0) | (0.9) |
| Contractual allowances | (1.2) | (1.0) |
| Medicare cap allowance | (0.7) | (0.9) |
| Total | 97.1% | 97.2% |
| Days of care | ||
| Homecare | 1,364,746 | 1,281,899 |
| Nursing home | 303,374 | 289,769 |
| Respite | 6,692 | 6,301 |
| Subtotal routine homecare and respite | 1,674,812 | 1,577,969 |
| Inpatient | 32,348 | 29,150 |
| Continuous care | 41,373 | 43,923 |
| Total | 1,748,533 | 1,651,042 |
| Number of days in relevant time period | 91 | 90 |
| Average daily census (days) | ||
| Homecare | 14,997 | 14,243 |
| Nursing home | 3,334 | 3,220 |
| Respite | 74 | 70 |
| Subtotal routine homecare and respite | 18,405 | 17,533 |
| Inpatient | 355 | 324 |
| Continuous care | 455 | 488 |
| Total | 19,215 | 18,345 |
| Total Admissions | 18,603 | 17,758 |
| Total Discharges | 18,196 | 17,739 |
| Average length of stay (days) | 90.7 | 91.3 |
| Median length of stay (days) | 14.0 | 15.0 |
| ADC by major diagnosis | ||
| Cerebro | 35.9% | 35.6% |
| Neurological | 21.4 | 19.9 |
| Cancer | 12.7 | 13.1 |
| Cardio | 15.9 | 16.9 |
| Respiratory | 8.3 | 8.2 |
| Other | 5.8 | 6.3 |
| Total | 100.0% | 100.0% |
| Admissions by major diagnosis | ||
| Cerebro | 21.1 | 20.7% |
| Neurological | 12.5 | 12.8 |
| Cancer | 28.3 | 28.0 |
| Cardio | 15.1 | 16.3 |
| Respiratory | 12.2 | 12.0 |
| Other | 10.8 | 10.2 |
| Total | 100.0% | 100.0% |
| Estimated uncollectible accounts as a percent of revenues | 1.2% | 1.0% |
| Accounts receivable -- | ||
| Days of revenue outstanding- excluding unapplied Medicare payments | 33.9 | 34.9 |
| Days of revenue outstanding- including unapplied Medicare payments | 26.1 | 23.3 |
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information
Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.
Market risk
As filed, 601 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2020, the Company had $160.0 million of variable rate debt outstanding. For each $10 million dollars borrowed under the credit facility, an increase or decrease of 100 basis points (1% point), increases or decreases the Company’s annual interest expense by $100,000.
The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.
Controls and procedures
As filed, 900 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 1,024 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The recent COVID-19 pandemic could have a material adverse effect on our business operations, results of operations, cash flows and financial position.
We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business and geographies, including how it will impact our customers, team members, suppliers, vendors, business partners and distribution channels. The COVID-19 pandemic has created significant volatility, uncertainty and economic disruption, which will adversely affect our business operations and may materially and adversely affect our results of operations, cash flows and financial position.
For additional information regarding specific risk factors related to the COVID-19 pandemic, see Management’s Discussion and Analysis of Financial Condition and Results of Operation under Part I., Item 2 of this Quarterly Report on Form 10-Q. There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-01 to 2020-03-31 | $515.8m | us-gaap:Revenues |
| Cost of revenue | 3 months2020-01-01 to 2020-03-31 | $351.7m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2020-01-01 to 2020-03-31 | $70.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-01-01 to 2020-03-31 | $79.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-01-01 to 2020-03-31 | $975.0k | us-gaap:InterestExpense |
| Income tax | 3 months2020-01-01 to 2020-03-31 | $13.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-01-01 to 2020-03-31 | $55.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-01-01 to 2020-03-31 | $3.38 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-01-01 to 2020-03-31 | $3.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-01-01 to 2020-03-31 | 16,516,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2020-01-01 to 2020-03-31 | $89.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-01-01 to 2020-03-31 | $19.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2020-01-01 to 2020-03-31 | $5.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2020-01-01 to 2020-03-31 | $100.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-03-31 | $29.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-31 | $198.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-31 | $1.28bn | us-gaap:Assets |
| Current liabilities | At period end2020-03-31 | $246.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-03-31 | $594.0m | us-gaap:Liabilities |
| Long-term debt | At period end2020-03-31 | $160.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2020-03-31 | $683.6m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2020-03-31 | 15,873,532 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000019584-20-000023. Last ingested by Listed: Nov 14, 2026, 12:29 ET. Listed shows no prices and gives no investment advice.